Company Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Adaptimmune Therapeutics plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.075 ^USD	+1.42%		+10.06%	+35.56%

Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 23	European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	MT

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Companyâs most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Number of employees: 449

USD in Million	2022	Weight	2023	Weight	Delta
Novel Cell Therapies 100.0 %	27	100.0 %	60	100.0 %	+122.05%

USD in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	27	100.0 %	60	100.0 %	+122.05%

Managers	Title	Age	Since
Helena Tayton-Martin FOU	Founder	57	07-12-31
Adrian Rawcliffe CEO	Chief Executive Officer	52	15-02-28
Gavin Wood DFI	Director of Finance/CFO	54	20-03-31
Joanna Brewer CTO	Chief Tech/Sci/R&D Officer	47	08-12-31
Elliot Norry CTO	Chief Tech/Sci/R&D Officer	61	15-06-30
William Bertrand COO	Chief Operating Officer	59	17-03-14
Juli P. Miller IRC	Investor Relations Contact	-	16-07-31
Sharp Kerry LAW	General Counsel	-	15-09-30
Phil Bassett PRN	Corporate Officer/Principal	-	-
John Lunger PRN	Corporate Officer/Principal	55	17-02-28

Members of the board	Title	Age	Since
Kristen Hege BRD	Director/Board Member	60	Oct. 31
Andrew Allen BRD	Director/Board Member	57	23-05-31
David Mott CHM	Chairman	58	14-08-31
Adrian Rawcliffe CEO	Chief Executive Officer	52	15-02-28
Ali Behbahani BRD	Director/Board Member	47	14-08-31
Garry Menzel BRD	Director/Board Member	59	23-05-31
John Furey BRD	Director/Board Member	59	18-07-04
Lawrence Alleva BRD	Director/Board Member	74	15-02-28
Priti Hegde BRD	Director/Board Member	52	23-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,480,950,456	223,044,163 ( 15.06 %)	0	15.06 %

Name	Equities	%	Valuation
Matrix Capital Management Co. LP 15.79 %	38,974,185	15.79 %	62 M $
EcoR1 Capital, LLC 11.10 %	27,404,070	11.10 %	43 M $
NEA Management Co. LLC 6.920 %	17,079,778	6.920 %	27 M $
Baillie Gifford & Co. 6.447 %	15,912,140	6.447 %	25 M $
Long Focus Capital Management LLC 4.897 %	12,086,915	4.897 %	19 M $
Baker Bros. Advisors LP 4.444 %	10,969,282	4.444 %	17 M $
MPM BioImpact, Inc 4.315 %	10,651,373	4.315 %	17 M $
PFM Health Sciences LP 4.223 %	10,423,135	4.223 %	16 M $
Bank of America, NA (Charlotte, North Carolina) 1.903 %	4,697,954	1.903 %	7 M $
Tang Capital Management LLC 1.777 %	4,387,238	1.777 %	7 M $

Name	Equities	%	Valuation
James Noble 1.438 %	8,145,700	1.438 %	2 M $
LSP Advisory BV 0.7904 %	4,477,854	0.7904 %	1 M $
Helena Tayton-Martin 0.3177 %	1,800,000	0.3177 %	474 102 $
Adrian Rawcliffe 0.1569 %	888,831	0.1569 %	234 109 $
William Bertrand 0.1162 %	658,208	0.1162 %	173 365 $
Garry Menzel 0.0995 %	563,522	0.0995 %	148 426 $
John Lunger 0.0846 %	479,027	0.0846 %	126 171 $
Charles Sigal 0.0648 %	367,038	0.0648 %	96 674 $
Cintia Piccina 0.0576 %	326,154	0.0576 %	85 906 $
Elliot Norry 0.0454 %	257,165	0.0454 %	67 735 $

Adaptimmune Therapeutics Plc

60 Jubilee Avenue Milton Park

OX14 4RX, Abingdon

+44 12 3543 0000

http://www.adaptimmune.com

address Adaptimmune Therapeutics plc(ADAP)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.075 USD

Average target price

3.6 USD

Spread / Average Target

+234.88%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ADAPTIMMUNE THERAPEUTICS PLC	+35.56%	275M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs